title: Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs.
abstract: Acyl coenzyme A:cholesterol acyltransferase (ACAT) is the enzyme that catalyzes the conversion of intracellular cholesterol into cholesteryl esters. Two ACAT isoforms, termed ACAT1 and ACAT2, have been described. ACAT1 is ubiquitously found, with high expression levels in macrophages, adrenals, sebaceous glands and foam cells from human atherosclerotic lesions. In contrast, ACAT2 expression is restricted to the intestine and the liver of mice and non-human primates. The reaction catalyzed by ACAT is essential for intestinal cholesterol absorption, synthesis and secretion of apolipoprotein B (apoB)-containing lipoproteins, and intracellular storage of cholesterol. Therefore, ACAT inhibitors would theoretically reduce plasma cholesterol levels by blocking cholesterol absorption from the diet and by reducing hepatic VLDL synthesis. Moreover, ACAT inhibition could limit the accumulation of cholesteryl esters in the cytoplasm of macrophages, thus reducing the formation of foam cells. In view of these attractive possibilities, a great deal of molecules with ACAT inhibitory properties have been synthesized in the last 20 years. However, only a few of them have reached clinical studies, mainly due to unexpected side effects. On the other hand, most of the compounds assayed in humans have not shown substantial hypolipidemic efficacy. The present article focuses on the current knowledge of the pharmacology of ACAT inhibitors, and, specifically, on the different pharmacological approaches used to evaluate these compounds as hypolipidemic and antiatherosclerotic agents.
authors.affiliation: Unitat de Farmacologia, Departament de Farmacologia i Quimica Terapeutica, Facultat de Farmacia, Universitat de Barcelona, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Alegret
authors.forename: G
authors.initials: G
authors.lastname: Llaverias
authors.forename: J S
authors.initials: JS
authors.lastname: Silvestre
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000494:pharmacology*; D019540:Area Under Curve; D001682:Biological Availability; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology*; D006207:Half-Life; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D050607:Organogold Compounds; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000502:physiology; D000097587:Sterol O-Acyltransferase 2
chemical_list: D018501:Antirheumatic Agents; D004791:Enzyme Inhibitors; D000960:Hypolipidemic Agents; D050607:Organogold Compounds; D002785:Sterol O-Acyltransferase; D000097587:Sterol O-Acyltransferase 2; C493492:sterol O-acyltransferase 1